What ArrePath does

ArrePath is a Princeton University spin-out founded in 2022 that applies proprietary AI/ML and bacterial imaging technologies to discover novel anti-infective drugs addressing antimicrobial resistance. Its lead program, AP-001, is an oral LpxH inhibitor targeting multidrug-resistant Enterobacterales for outpatient urinary tract infections, with pre-development candidate nomination targeted for Q2 2026; a second program targets non-tuberculous mycobacterial (NTM) lung disease, and a third program (Project 3) extends the platform beyond infectious disease. Headquartered at 303A College Road East, Princeton, NJ, the company employs 11-50 people whose leadership team has contributed to the discovery, development, or approval of nine antibiotics.

The platform combines heterogeneous bioactivity rank-order modeling, scaffold-agnostic molecular representations with zero-shot generalization to new chemistry, ML-guided phenotypic high-throughput screening, and an indication-first parallel design workflow. Performance has been validated in a live discovery program: lead optimization completed in 17 months versus a typical 4-5 years, using 697 compounds versus 1,200-2,500 and an 8-person team versus 20-25. The zero-shot oral bioavailability model achieved AUC-ROC of approximately 0.72 versus 0.56 (public Random Forest) and 0.51 (public GNN), and the company improved oral bioavailability in its lead series from below 10% to over 80%. AP-001 demonstrates MIC90 ≤4 µg/mL across MDR, MBL, and CRE isolates with a low resistance frequency of approximately 1×10⁻⁹. The platform IP is held under exclusive license option from Princeton University based on founder Zemer Gitai's research.

ArrePath is pre-revenue and operates a B2B drug discovery and licensing model, seeking to out-license developed compounds and form co-development partnerships with pharmaceutical companies for clinical development and commercialization. Operations are funded through equity capital (a $20 million seed in March 2022 led by Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures, plus an undisclosed 2025 follow-on led by Boehringer Ingelheim Venture Fund with new investor AB Magnitude) and non-dilutive grants (CARB-X US$3.7M in April 2025; PACE £1M in November 2024). Pricing is not applicable at the current stage. Leadership includes CEO Kevin Krause (formerly CSO of AN2 Therapeutics), CSO Alita Miller (contributed to Xacduro and zoliflodacin at Entasis), CTO Kurt Thorn (former Senior Director of Data Science at Zymergen), and Chairman Diego Miralles (former CEO of Vividion and Laronde).

Name

ArrePath

Legal name

ArrePath, Inc.

Website

https://arrepath.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

ArrePath is an AI/ML-driven anti-infective drug discovery company spun out of Princeton University in 2022, developing novel oral antibiotics against drug-resistant infections including outpatient UTI and NTM lung disease for licensing to pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Anti-Infective Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Anti-infective drug discovery
• Machine learning platform
• Antibiotic pipeline development
• Phenotypic drug screening
• Antimicrobial resistance research

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pipeline Development and Licensing: Developing novel antibiotic pipeline programs (outpatient UTI, NTM lung disease) intended for licensing to pharmaceutical partners or eventual commercialization. Pre-revenue stage company.
2. Non-Dilutive Funding (Grants): Receiving grant funding from CARB-X ($3.7M) and PACE (£1M) to advance lead optimization programs. These funds support R&D without equity dilution.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

ArrePath operates an AI/ML drug discovery platform that combines heterogeneous bioactivity data modeling, scaffold-agnostic molecular representations, indication-first parallel design, ML-guided phenotypic high-throughput screening, oral bioavailability prediction, and imaging-based mechanism-of-action prediction to discover novel anti-infective small molecules. The platform currently supports an internal pipeline of antibiotic programs intended for out-licensing or co-development with larger pharmaceutical partners.

Product overview

ArrePath operates as an AI-driven drug discovery company with a unified platform approach. Their core offering is a proprietary machine learning platform that combines heterogeneous bioactivity data processing, phenotypic imaging, and indication-first drug design to discover novel anti-infectives. The company applies this platform across a differentiated pipeline including: AP-001 (Project 1), an oral LpxH inhibitor for outpatient UTI currently in late lead optimization; Project 2 targeting NTM lung disease and tuberculosis; and Project 3 extending into non-infectious disease therapeutic areas. The platform's modular design enables cross-scaffold, cross-assay rank-order training that generalizes to new chemistry where conventional approaches and public models fail.

Differentiator

Problem solved

Functional benefit

Products and services

• AP-001 (Outpatient UTI Program) Novel oral small molecule LpxH inhibitor for outpatient urinary tract infections caused by multidrug-resistant Enterobacterales and carbapenem-resistant Enterobacterales (CRE), with potential for both oral and IV administration. Intended for out-licensing or co-development with pharmaceutical partners.
• NTM Lung Disease Program Novel oral compound classes targeting non-tuberculous mycobacteria including M. abscessus and M. avium complex (MAC), as well as tuberculosis, intended for out-licensing or co-development with pharmaceutical partners.
• Non-Infectious Disease Discovery Program Discovery program applying ArrePath's AI/ML platform and workflow to therapeutic areas beyond infectious disease, leveraging the generalizable data treatment, molecular representations, and indication-first design.

Quantifiable outcome

• Lead optimization completed in 17 months vs typical 4-5 years, with 697 compounds vs typical 1,200-2,500, using 8-person team vs typical 20-25
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Two partnerships are on record, tiered supporting and core.

• Scientific Advisory Board MemberssupportingStrategic or Co-development Partner · 18 November 2022SAB includes Zemer Gitai (Founder, Princeton), Barbara Engelhardt (Stanford), Todd Black (TB Alliance), and appointed Connor Coley (MIT) and Paul Hergenrother (UIUC) in November 2022.
• Princeton UniversitycoreStrategic or Co-development PartnerArrePath is a spin-out from Princeton University with exclusive option to license platform technology IP from research published in Cell by Zemer Gitai. Founder Zemer Gitai is Edwin Grant Conklin Professor of Biology at Princeton.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Spero Therapeutics: Late-stage clinical biopharmaceutical company developing antibiotics for MDR bacterial infections, including oral and IV agents for UTIs and other serious infections. Comparable peer on modality (small-molecule antibiotics), target indications, and commercial-stage focus on the anti-infective market.
• Entasis Therapeutics: Anti-infective drug developer acquired by Innoviva in 2022; focused on serious bacterial infections including Xacduro (sulbactam-durlobactam) for Acinetobacter. ArrePath's CSO Alita Miller was SVP of Biology at Entasis and contributed to Xacduro and zoliflodacin, making it a closely comparable anti-infective peer.
• AN2 Therapeutics: Anti-infective developer focused on NTM (non-tuberculous mycobacterial) lung disease with epetraborole. ArrePath's CEO Kevin Krause was Chief Strategy Officer at AN2 leading its NTM program — directly overlapping on target indication, and ArrePath's Project 2 also targets NTM lung disease.
• Bugworks Research: Clinical-stage biopharmaceutical company developing novel classes of antibiotics targeting MDR Gram-negative bacteria. Comparable peer on modality, indication (MDR Gram-negative infections), and stage of development, with similar out-licensing and partnership-driven commercialization approach.
• Iterum Therapeutics: Anti-infective company developing oral antibiotics for complicated urinary tract infections (cUTI) and other multi-drug resistant infections. Directly comparable to ArrePath's lead AP-001 program in terms of indication (UTI), modality (oral antibiotic), and target patient population (MDR/Enterobacterales).
• VenatoRx Pharmaceuticals: Private clinical-stage biopharmaceutical company developing novel antibiotics to combat MDR Gram-negative infections and difficult-to-treat bacterial pathogens. Closely comparable peer on modality (novel small molecule antibiotics), target pathogens (MDR Enterobacterales), and out-licensing-driven commercialization model.

Broad incumbents

• Vir Biotechnology: Public clinical-stage immunology company developing treatments for serious infectious diseases including hepatitis B, influenza, and HIV. Comparable on anti-infective focus and large-pharma partnership model, but operates at much larger scale and is not AI-platform-led.
• Insitro: AI/ML-driven drug discovery company applying machine learning to biology across multiple therapeutic areas including neuroscience and metabolic disease. Comparable on platform-driven AI drug discovery approach, but broader in scope and not focused on anti-infectives.
• Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning across multiple therapeutic areas. Comparable on the AI/ML drug discovery platform paradigm, but operates at vastly larger scale and across broader indications rather than specializing in anti-infectives.

Emerging players

• Atomwise: AI-driven small molecule drug discovery company using structure-based deep learning for hit identification across multiple therapeutic areas. Comparable as an AI/ML platform for small molecule discovery, with overlapping technology approach but broader therapeutic focus and different target product profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ArrePath

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ArrePath